US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CAR-T Concept

1,404.00

+12.880.93%

Number of Gainers:2

Number of Losers:- -

Number of Flat:- -

PE:- -

High:1,413.58

Open:1,390.95

Low:1,390.42

Close:1,391.11

Loading ...

Sui Ecosystem Token Surges, SEND Sees 22% 24-hour Price Increase

Gilead Sciences Inc. Chief Commercial Officer Johanna Mercier Reports Disposal of Common Shares

Healthcare Stocks Are So Bad, They're Good. What to Buy Now. -- Barrons.com

Gilead Sciences Says Trodelvy Met Primary Endpoint in Phase 3 Breast Cancer Trial

MT Newswires Live

BRIEF-ASCENT-03 - Trodelvy Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors

Gilead announces ASCENT-03 study meets primary endpoint

Gilead Sciences Announces Breakthrough Phase 3 Results: Trodelvy Significantly Improves Survival in First-line Metastatic Triple-Negative Breast Cancer

Gilead Sciences Inc - Trodelvy Safety Profile Consistent With Prior Studies in Ascent-03

THOMSON REUTERS

Gilead Sciences Inc - Ascent-03 Study Meets Primary Endpoint With Significant Improvement in Pfs

THOMSON REUTERS

Ascent-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-Line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors

THOMSON REUTERS

Sector Update: Health Care Stocks Retreat Thursday Afternoon

MT Newswires Live

HOOKIPA to Sell HBV, HIV Program Assets to Gilead; Shares Rise

MT Newswires Live

Gilead put volume heavy and directionally bearish

Bitget has launched U-based TGT and BLUE perpetual contracts

Hookipa Pharma Sells Assets to Gilead Sciences

Hookipa Pharma Inc. Announces Asset Sale Agreement with Gilead Sciences for HB-400 and HB-500 Programs

Due to the "Bithumb Listing" effect, BLUE surged above $0.13

Bithumb has added Bluefin (BLUE) for trading.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4578/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4578","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","market":"US","secType":"PLATE","nameCN":"CAR-T Concept","latestPrice":1403.9991,"timestamp":1749153599999,"preClose":1391.1146,"halted":0,"volume":11894162,"delay":0,"changeRate":0.009262,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":12.884521,"latestTime":"06-05 16:00:00 EDT","open":1390.9452,"high":1413.579,"low":1390.4197,"amount":1325502377.840955,"amplitude":0.016648,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749196800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":6.359502,"peRate":19.436277,"turnoverRate":0.003904,"increases":2,"decrements":0,"flats":0,"marketCap":368184926208,"floatMarketCap":349795237888},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","high":1413.579,"amplitude":0.016648,"preClose":1391.1146,"low":1390.4197,"pbRate":"6.359502","latestPrice":1403.9991,"volume":11894162,"delay":0,"open":1390.9452,"prevYearClose":1164.883,"prevWeekClose":1387.2515,"prevMonthClose":1387.2515,"prevQuarterClose":1364.0579,"fiveDayClose":1367.9299,"twentyDayClose":1303.775,"sixtyDayClose":1374.4496,"secType":"PLATE","market":"US","turnoverRate":0.003904,"peRate":19.436277,"marketCap":368184926208,"floatMarketCap":349795237888,"timestamp":1749153599999,"nameCN":"CAR-T Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4578\",,,,undefined,":{"bkCode":"BK4578","up":2,"down":0,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4578\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2538843395","title":"Sui Ecosystem Token Surges, SEND Sees 22% 24-hour Price Increase","url":"https://stock-news.laohu8.com/highlight/detail?id=2538843395","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538843395?lang=en_us&edition=fundamental","pubTime":"2025-05-27 11:28","pubTimestamp":1748316480,"startTime":"0","endTime":"0","summary":"BlockBeats News, May 27, according to HTX market data, the Sui ecosystem tokens have seen a revival, including:SEND's market cap is now $39.26 million, with a 24-hour increase of 22%;HIPPO's market cap is now $30.58 million, with a 24-hour increase of 10.1%;BLUE's market cap is now $38.80 million, with a 24-hour increase of 8.8%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/295621","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["HIPO","BK4139","BK4578","BK4556","BLUE"],"gpt_icon":0},{"id":"2537715197","title":"Gilead Sciences Inc. Chief Commercial Officer Johanna Mercier Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2537715197","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537715197?lang=en_us&edition=fundamental","pubTime":"2025-05-24 03:17","pubTimestamp":1748027827,"startTime":"0","endTime":"0","summary":"Johanna Mercier, Chief Commercial Officer of Gilead Sciences Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 23, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nNDL7f4HdK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Gilead Sciences Inc. Chief Commercial Officer Johanna Mercier Reports Disposal of Common Shares","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","LU1585245621.USD","LU2087621335.USD","IE00B19Z3B42.SGD","LU2089984988.USD","IE00BKVL7J92.USD","LU0889565916.HKD","LU1674673428.USD","BK4585","IE00BSNM7G36.USD","LU0320765992.SGD","IE0002270589.USD","LU1778281490.HKD","LU2468319806.SGD","LU0109394709.USD","BK4532","BK4578","LU1066051498.USD","LU0289739699.SGD","BK4588","IE00B7SZLL34.SGD","BK4566","BK4550","GILD","IE00B3T34201.USD","LU0058720904.USD","IE00BZ1G4Q59.USD","LU1066053197.SGD","LU0823416689.USD","LU1839511570.USD","BK4568","LU1674673691.USD","IE00B19Z3581.USD","LU1430594728.SGD","LU1571399168.USD","LU0234570918.USD","BK4139"],"gpt_icon":0},{"id":"2537132425","title":"Healthcare Stocks Are So Bad, They're Good. What to Buy Now. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2537132425","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537132425?lang=en_us&edition=fundamental","pubTime":"2025-05-23 21:57","pubTimestamp":1748008620,"startTime":"0","endTime":"0","summary":"Healthcare stocks have been performing so badly for so long, it's hard to tell whether they need a doctor or a mortician. They may finally be on the verge of a revival.Sometimes, though, these sentiment shifts get too extreme -- and now may be one of those moments. One way market technicians try to compare indexes is by looking at the change in the ratio of one to the other. Jason Goepfert, founder and senior research analyst at SentimenTrader, notes that the ratio of the price of the healthcare index relative to the S&P 500 fell more than 35% from its most recent high, something that had only occurred seven times before over the past 100 years. That type of relative decline has typically been a good time to buy the sector, which has averaged a return of 17% over the subsequent 12 months.Insiders, however, are taking the long view. Goepfert notes that they've been scooping up shares of beaten-up UnitedHealth and Humana, among others, with the buying outpacing selling. That, too, has be","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1430594728.SGD","BK4534","IVV","LU2089984988.USD","LU0289739699.SGD","IE00BSNM7G36.USD","FDN","LU0823416689.USD","OEX","BK4578","LU2468319806.SGD","LU1839511570.USD","IE00B19Z3B42.SGD","LU1571399168.USD","GILD","LU1585245621.USD","UNH","LU1066051498.USD","VOO","BK4504","UPRO","LU0320765992.SGD","LU1778281490.HKD","BK4568",".SPX","LU2087621335.USD","SH","OEF","IE00B19Z3581.USD","BK4550","BK4588","IE00B7SZLL34.SGD","LU1066053197.SGD","MESmain","IE00BZ1G4Q59.USD","IE00B3T34201.USD","BK4532","LU1674673691.USD","LU0109394709.USD","SPXU","SPY","BK4566","BK4559","HCSG","LU0058720904.USD","ESmain","SDS","SSO","LU0234570918.USD","LU1674673428.USD"],"gpt_icon":1},{"id":"2537131674","title":"Gilead Sciences Says Trodelvy Met Primary Endpoint in Phase 3 Breast Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2537131674","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537131674?lang=en_us&edition=fundamental","pubTime":"2025-05-23 21:00","pubTimestamp":1748005217,"startTime":"0","endTime":"0","summary":"Gilead Sciences  said Friday that its experimental drug, trodelvy, met the primary endpoint in a phase 3 trial, showing a statistically significant and clinically meaningful improvement in progression-free survival over chemotherapy in patients with a type of breast cancer who are not candidates for immunotherapy.The company said the drug's safety profile in the study was consistent with previous trials, with no new safety signals observed.The drugmaker said overall survival, a key secondary endpoint, was not yet mature at the time of analysis, and further monitoring is underway.Gilead said it is also evaluating trodelvy in multiple ongoing phase 3 studies across various tumor types, including HER2-negative breast cancer, lung, and gynecologic cancers.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GILD","IE0002270589.USD","LU0234570918.USD","IE00B19Z3581.USD","BK4566","BK4550","LU0823416689.USD","LU0058720904.USD","LU1778281490.HKD","LU1571399168.USD","LU2087621335.USD","LU1066051498.USD","LU1430594728.SGD","LU0289739699.SGD","LU1674673428.USD","IE00BKVL7J92.USD","LU0889565916.HKD","LU1674673691.USD","BK4585","BK4568","BK4583","LU0320765992.SGD","LU2468319806.SGD","BK4532","IE00BSNM7G36.USD","IE00B3T34201.USD","LU0109394709.USD","BK4139","IE00B7SZLL34.SGD","LU1839511570.USD","LU2089984988.USD","IE00B19Z3B42.SGD","LU1066053197.SGD","IE00BZ1G4Q59.USD","BK4588","BK4578","LU1585245621.USD"],"gpt_icon":0},{"id":"2537318971","title":"BRIEF-ASCENT-03 - Trodelvy Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2537318971","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537318971?lang=en_us&edition=fundamental","pubTime":"2025-05-23 20:49","pubTimestamp":1748004563,"startTime":"0","endTime":"0","summary":"BRIEF-ASCENT-03 - Trodelvy Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nTUABJLBB8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1839511570.USD","LU0234570918.USD","BK4588","BK4532","IE00B19Z3581.USD","LU1674673428.USD","LU1571399168.USD","LU0058720904.USD","LU1674673691.USD","LU1430594728.SGD","IE00BZ1G4Q59.USD","IE00B7SZLL34.SGD","LU2087621335.USD","LU0289739699.SGD","BK4578","IE00B3T34201.USD","LU1066051498.USD","LU1066053197.SGD","LU2468319806.SGD","BK4568","LU0320765992.SGD","BK4566","LU1585245621.USD","IE0002270589.USD","LU0823416689.USD","IE00BKVL7J92.USD","BK4550","IE00B19Z3B42.SGD","GILD","LU0109394709.USD","LU0889565916.HKD","LU2089984988.USD","LU1778281490.HKD","IE00BSNM7G36.USD","BK4585","BK4583","BK4139"],"gpt_icon":0},{"id":"2537813975","title":"Gilead announces ASCENT-03 study meets primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2537813975","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537813975?lang=en_us&edition=fundamental","pubTime":"2025-05-23 20:40","pubTimestamp":1748004013,"startTime":"0","endTime":"0","summary":"Gilead (GILD) announced topline results from the Phase 3 ASCENT-03 study of Trodelvy. The study met its primary endpoint, demonstrating a highly st...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gilead-announces-ascent-03-study-meets-primary-endpoint-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gilead-announces-ascent-03-study-meets-primary-endpoint-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B7SZLL34.SGD","LU2468319806.SGD","IE0002270589.USD","LU0109394709.USD","BK4532","LU0234570918.USD","LU1571399168.USD","IE00B19Z3581.USD","BK4588","LU0889565916.HKD","IE00B19Z3B42.SGD","BK4566","BK4578","LU1674673428.USD","BK4550","LU0289739699.SGD","BK4139","BK4583","LU2089984988.USD","LU1674673691.USD","LU1585245621.USD","LU0823416689.USD","LU2087621335.USD","GILD","IE00BZ1G4Q59.USD","LU1839511570.USD","LU0320765992.SGD","LU0058720904.USD","IE00BKVL7J92.USD","BK4585","LU1430594728.SGD","LU1066051498.USD","IE00B3T34201.USD","LU1778281490.HKD","IE00BSNM7G36.USD","LU1066053197.SGD","BK4568"],"gpt_icon":0},{"id":"2537139691","title":"Gilead Sciences Announces Breakthrough Phase 3 Results: Trodelvy Significantly Improves Survival in First-line Metastatic Triple-Negative Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2537139691","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537139691?lang=en_us&edition=fundamental","pubTime":"2025-05-23 20:30","pubTimestamp":1748003444,"startTime":"0","endTime":"0","summary":"Gilead Sciences Announces Breakthrough Phase 3 Results: Trodelvy Significantly Improves Survival in First-line Metastatic Triple-Negative Breast Cancer. Gilead Sciences Inc. announced positive topline results from the Phase 3 ASCENT-03 study of Trodelvy , highlighting its significant impact on patients with first-line metastatic triple-negative breast cancer  who are not candidates for PD-1/PD-L1 inhibitors. The study demonstrated a statistically significant and clinically meaningful improvement in progression-free survival  compared to standard chemotherapy. This marks the second positive Phase 3 trial where Trodelvy has shown benefits over standard care for this patient group. The results suggest Trodelvy could become the backbone treatment and the first antibody-drug conjugate for all patients across first-line metastatic TNBC. This development addresses an urgent need for innovative treatment options in the early stages of mTNBC, where traditional chemotherapy has been the standard","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nNDL9r684h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066051498.USD","BK4139","LU2089984988.USD","LU1674673691.USD","LU0109394709.USD","IE0002270589.USD","LU1674673428.USD","LU0058720904.USD","LU0889565916.HKD","IE00B7SZLL34.SGD","LU0289739699.SGD","IE00B3T34201.USD","LU1839511570.USD","BK4583","GILD","BK4585","LU2087621335.USD","LU2468319806.SGD","LU1571399168.USD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","BK4578","IE00BKVL7J92.USD","LU0320765992.SGD","BK4566","LU0234570918.USD","BK4532","LU1430594728.SGD","LU1066053197.SGD","IE00BSNM7G36.USD","LU0823416689.USD","BK4568","LU1585245621.USD","LU1778281490.HKD","IE00BZ1G4Q59.USD","BK4550","BK4588"],"gpt_icon":0},{"id":"2537139664","title":"Gilead Sciences Inc - Trodelvy Safety Profile Consistent With Prior Studies in Ascent-03","url":"https://stock-news.laohu8.com/highlight/detail?id=2537139664","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537139664?lang=en_us&edition=fundamental","pubTime":"2025-05-23 20:30","pubTimestamp":1748003400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nTUABJLBB8:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1674673428.USD","IE00BKVL7J92.USD","BK4578","LU1778281490.HKD","LU0058720904.USD","BK4583","LU0289739699.SGD","LU0320765992.SGD","LU1430594728.SGD","LU0234570918.USD","IE00BSNM7G36.USD","LU1839511570.USD","IE00B19Z3B42.SGD","LU1066051498.USD","LU1066053197.SGD","LU2468319806.SGD","IE00B3T34201.USD","BK4568","LU1585245621.USD","BK4139","BK4550","LU1674673691.USD","IE0002270589.USD","BK4588","GILD","LU2087621335.USD","IE00B7SZLL34.SGD","BK4585","BK4532","LU0109394709.USD","BK4566","LU1571399168.USD","IE00B19Z3581.USD","IE00BZ1G4Q59.USD","LU0823416689.USD","LU2089984988.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2537139656","title":"Gilead Sciences Inc - Ascent-03 Study Meets Primary Endpoint With Significant Improvement in Pfs","url":"https://stock-news.laohu8.com/highlight/detail?id=2537139656","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537139656?lang=en_us&edition=fundamental","pubTime":"2025-05-23 20:30","pubTimestamp":1748003400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nTUABJLBB8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1839511570.USD","LU0234570918.USD","BK4588","BK4532","IE00B19Z3581.USD","LU1674673428.USD","LU1571399168.USD","LU0058720904.USD","LU1674673691.USD","LU1430594728.SGD","IE00BZ1G4Q59.USD","IE00B7SZLL34.SGD","LU2087621335.USD","LU0289739699.SGD","BK4578","IE00B3T34201.USD","LU1066051498.USD","LU1066053197.SGD","LU2468319806.SGD","BK4568","LU0320765992.SGD","BK4566","LU1585245621.USD","IE0002270589.USD","LU0823416689.USD","IE00BKVL7J92.USD","BK4550","IE00B19Z3B42.SGD","GILD","LU0109394709.USD","LU0889565916.HKD","LU2089984988.USD","LU1778281490.HKD","IE00BSNM7G36.USD","BK4585","BK4583","BK4139"],"gpt_icon":0},{"id":"2537139654","title":"Ascent-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-Line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2537139654","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537139654?lang=en_us&edition=fundamental","pubTime":"2025-05-23 20:30","pubTimestamp":1748003400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nTUABJLBB8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0320765992.SGD","BK4568","BK4588","LU0889565916.HKD","IE0002270589.USD","LU1674673691.USD","BK4550","BK4566","LU1066053197.SGD","BK4585","LU0289739699.SGD","IE00B7SZLL34.SGD","GILD","LU1066051498.USD","LU1571399168.USD","LU1778281490.HKD","IE00BZ1G4Q59.USD","IE00BSNM7G36.USD","LU2468319806.SGD","LU1839511570.USD","BK4578","LU0058720904.USD","IE00B19Z3581.USD","BK4583","LU0823416689.USD","LU2087621335.USD","BK4139","LU0109394709.USD","LU1674673428.USD","IE00B3T34201.USD","LU1585245621.USD","LU2089984988.USD","IE00BKVL7J92.USD","BK4532","LU1430594728.SGD","LU0234570918.USD","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"2537373929","title":"Sector Update: Health Care Stocks Retreat Thursday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2537373929","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537373929?lang=en_us&edition=fundamental","pubTime":"2025-05-23 01:56","pubTimestamp":1747936573,"startTime":"0","endTime":"0","summary":"Health care stocks declined Thursday afternoon, with the NYSE Health Care Index down 0.7% and the Health Care Select Sector SPDR Fund (XLV) shedding 0.6%.The iShares Biotechnology ETF (IBB) was fracti","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HOOK","LU1066051498.USD","VIGL","LU0320765992.SGD","IE00BZ1G4Q59.USD","BK4583","BK4585","LU0058720904.USD","LU0289739699.SGD","LU1778281490.HKD","RENB","BK4109","IE00BFXG1179.USD","LU1066053197.SGD","IE0002270589.USD","IE00B19Z3B42.SGD","IE00B3T34201.USD","LU1430594728.SGD","DNA","BK4505","LU0109394709.USD","BK4082","BK4578","DNA.AU","GILD","BK4007","IBB","BK4198","LU1674673691.USD","LU1839511570.USD","BK4532","BK4566","LU1585245621.USD","IE00B19Z3581.USD","LU1571399168.USD","LU2087621335.USD","BK4588","LU2468319806.SGD","LU0889565916.HKD","LU2089984988.USD","XLV","LU0823416689.USD","LU0234570918.USD","BK7078","BK4581","IE00BSNM7G36.USD","POAI","SNY","BK4568","BK4139"],"gpt_icon":0},{"id":"2537923783","title":"HOOKIPA to Sell HBV, HIV Program Assets to Gilead; Shares Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2537923783","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537923783?lang=en_us&edition=fundamental","pubTime":"2025-05-23 00:06","pubTimestamp":1747929967,"startTime":"0","endTime":"0","summary":"HOOKIPA Pharma  said Thursday it struck a deal to sell its key assets from its HB-400 program for hepatitis B virus and HB-500 program for human immunodeficiency virus program to Gilead Sciences  for up to $10 million.These programs are currently in clinical development, the company said in a regulatory filing. Gilead will not acquire other assets, including its HB-500 phase 1b clinical trial.HOOKIPA said it will receive $3 million upfront at closing, with up to $7 million due in three phases.Shares of HOOKIPA rose past 11% in recent trading.Price: 1.72, Change: +0.20, Percent Change: +13.16","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE0002270589.USD","BK4568","LU2468319806.SGD","LU1066051498.USD","BK4578","BK4139","BK4505","LU0058720904.USD","LU1778281490.HKD","BK4585","LU1066053197.SGD","IE00BKVL7J92.USD","LU2089984988.USD","BK4550","BK4588","LU0234570918.USD","LU0320765992.SGD","LU1571399168.USD","IE00BZ1G4Q59.USD","BK4532","IE00B19Z3B42.SGD","GILD","IE00BSNM7G36.USD","LU1674673691.USD","LU2087621335.USD","LU0289739699.SGD","LU1585245621.USD","HOOK","LU0109394709.USD","LU1839511570.USD","BK4566","LU1430594728.SGD","LU1674673428.USD","IE00B7SZLL34.SGD","BK4583","LU0889565916.HKD","IE00B19Z3581.USD","IE00B3T34201.USD","LU0823416689.USD"],"gpt_icon":0},{"id":"2537949928","title":"Gilead put volume heavy and directionally bearish","url":"https://stock-news.laohu8.com/highlight/detail?id=2537949928","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537949928?lang=en_us&edition=fundamental","pubTime":"2025-05-22 23:15","pubTimestamp":1747926911,"startTime":"0","endTime":"0","summary":"Bearish flow noted in Gilead (GILD) with 14,448 puts trading, or 5x expected. Most active are Jun-25 100 puts and Jun-25 106 puts, with total volum...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gilead-put-volume-heavy-and-directionally-bearish-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gilead-put-volume-heavy-and-directionally-bearish-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1839511570.USD","BK4550","IE0002270589.USD","LU1778281490.HKD","LU1674673691.USD","LU1674673428.USD","IE00B7SZLL34.SGD","LU0823416689.USD","BK4568","IE00BSNM7G36.USD","LU0109394709.USD","LU0320765992.SGD","LU1066051498.USD","LU2089984988.USD","BK4585","BK4532","BK4139","LU2087621335.USD","LU1066053197.SGD","BK4588","IE00B3T34201.USD","LU0058720904.USD","LU0234570918.USD","BK4566","LU1585245621.USD","LU1430594728.SGD","BK4578","BK4583","IE00B19Z3B42.SGD","LU0889565916.HKD","LU0289739699.SGD","GILD","LU1571399168.USD","IE00B19Z3581.USD","LU2468319806.SGD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2537794056","title":"Bitget has launched U-based TGT and BLUE perpetual contracts","url":"https://stock-news.laohu8.com/highlight/detail?id=2537794056","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537794056?lang=en_us&edition=fundamental","pubTime":"2025-05-22 22:35","pubTimestamp":1747924500,"startTime":"0","endTime":"0","summary":"BlockBeats News, May 22, according to an official announcement, Bitget has announced the launch of U-based TGT and BLUE perpetual contracts, with leverage ranges of 1-20x, and the contract trading BOT will be opened simultaneously.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/295113","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["BK4578","BK4556","BLUE","BK4139"],"gpt_icon":0},{"id":"2537949585","title":"Hookipa Pharma Sells Assets to Gilead Sciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2537949585","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537949585?lang=en_us&edition=fundamental","pubTime":"2025-05-22 20:30","pubTimestamp":1747917050,"startTime":"0","endTime":"0","summary":"An announcement from Hookipa Pharma ( ($HOOK) ) is now available. On May 21, 2025, Hookipa Pharma and its subsidiary entered into an Asset Purchase...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/hookipa-pharma-sells-assets-to-gilead-sciences?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/hookipa-pharma-sells-assets-to-gilead-sciences?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1839511570.USD","BK4550","IE0002270589.USD","LU1778281490.HKD","LU1674673691.USD","LU1674673428.USD","IE00B7SZLL34.SGD","LU0823416689.USD","BK4568","IE00BSNM7G36.USD","LU0109394709.USD","LU0320765992.SGD","LU1066051498.USD","LU2089984988.USD","BK4585","BK4532","BK4139","LU2087621335.USD","LU1066053197.SGD","BK4588","IE00B3T34201.USD","LU0058720904.USD","LU0234570918.USD","BK4566","LU1585245621.USD","LU1430594728.SGD","BK4578","BK4583","IE00B19Z3B42.SGD","LU0889565916.HKD","LU0289739699.SGD","GILD","LU1571399168.USD","IE00B19Z3581.USD","LU2468319806.SGD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2537945970","title":"Hookipa Pharma Inc. Announces Asset Sale Agreement with Gilead Sciences for HB-400 and HB-500 Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2537945970","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537945970?lang=en_us&edition=fundamental","pubTime":"2025-05-22 20:01","pubTimestamp":1747915300,"startTime":"0","endTime":"0","summary":"Hookipa Pharma Inc. has announced an agreement to sell certain assets to Gilead Sciences, Inc. The transaction, dated May 21, 2025, involves the sale of assets primarily related to Hookipa's HB-400 program, which is currently in clinical development for treating hepatitis B virus, as well as certain assets from the HB-500 program, focused on the human immunodeficiency virus. Gilead will pay up to $10 million for these assets, with $3 million due at closing and the remainder contingent on the completion of a three-phase transfer plan. The deal excludes certain assets, such as the Phase 1b clinical trial of HB-500 and other clinical and preclinical programs. Hookipa Pharma is collaborating with Gilead under an existing research collaboration and license agreement.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nNDLbg7FZG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOOK","BK4139","LU1066051498.USD","BK4583","LU0889565916.HKD","LU2468319806.SGD","IE00B19Z3581.USD","LU0320765992.SGD","BK4532","LU1571399168.USD","LU1585245621.USD","LU1674673428.USD","IE00B19Z3B42.SGD","LU0109394709.USD","GILD","IE00BSNM7G36.USD","LU0289739699.SGD","IE00B3T34201.USD","LU2089984988.USD","BK4550","IE0002270589.USD","LU0823416689.USD","LU1778281490.HKD","LU1430594728.SGD","IE00BZ1G4Q59.USD","IE00B7SZLL34.SGD","BK4505","BK4566","IE00BKVL7J92.USD","LU1066053197.SGD","LU1839511570.USD","LU0058720904.USD","LU2087621335.USD","LU1674673691.USD","BK4568","BK4578","BK4585","BK4588","LU0234570918.USD"],"gpt_icon":0},{"id":"2537446995","title":"Due to the \"Bithumb Listing\" effect, BLUE surged above $0.13","url":"https://stock-news.laohu8.com/highlight/detail?id=2537446995","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537446995?lang=en_us&edition=fundamental","pubTime":"2025-05-22 13:32","pubTimestamp":1747891920,"startTime":"0","endTime":"0","summary":"BlockBeats News, May 22nd, according to HTX market data, influenced by the \"Listed on Bithumb\" news, Bluefin (BLUE) surged above $0.13, currently trading at $0.1324, a 24-hour gain of 23.07%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/294984","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["BK4556","BK4578","BK4139","BLUE"],"gpt_icon":0},{"id":"2537995416","title":"Bithumb has added Bluefin (BLUE) for trading.","url":"https://stock-news.laohu8.com/highlight/detail?id=2537995416","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537995416?lang=en_us&edition=fundamental","pubTime":"2025-05-22 13:27","pubTimestamp":1747891620,"startTime":"0","endTime":"0","summary":"BlockBeats News, May 22, according to official sources, the South Korean cryptocurrency exchange Bithumb has added Bluefin (BLUE) for trading.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/294982","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["BLUE","BK4578","BK4139","BK4556"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":38,"code":"91000000","status":"200"}]}}